TY  - JOUR
AU  - Reschke, Robin
AU  - Hassel, Jessica
TI  - Tebentafusp—the first drug with a significant and persistent survival benefit in metastatic uveal melanoma.[Tebentafusp – erstes Medikament mit signifikantem und andauerndem Überlebensvorteil beim metastasierten Uveamelanom.]
JO  - Best Practice Onkologie
VL  - 20
IS  - 5
SN  - 0946-4565
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2025-01026
SP  - 186 - 189
PY  - 2025
AB  - Uveal melanoma, also known as choroidal melanoma, is a rare form of melanoma that arises from pigment cells of the eye, primarily the choroid. It can also affect the iris or the ciliary body and often metastasizes to distant sites, primarily the liver. In contrast to other types of melanoma, uveal melanoma responds poorly to treatment with checkpoint inhibitors; it is thus associated with a worse prognosis. The new immunotherapeutic tebentafusp, however, is a promising treatment option for patients with human leukocyte antigen (HLA) type A*02:01. Tebentafusp is a bispecific protein that specifically recognizes a peptide of the melanocyte differentiation antigen gp100 and activates T cells. This leads to polyclonal activation of T cells in the tumor environment and antitumor immune defense. A phase III trial has shown that tebentafusp significantly improves the overall survival of patients with metastatic uveal melanoma in comparison to other treatments. After 3 years, 27
LB  - PUB:(DE-HGF)16
DO  - DOI:10.1007/s11654-025-00653-0
UR  - https://inrepo02.dkfz.de/record/301484
ER  -